Aktuellt
SENASTE
Redeye comments on Scandion Oncology’s Q4 2022 report, with a new CEO in place and two study readouts in 2023e. However, we believe that the most important trigger for Scandion’s share constitutes CORIST part 4 efficacy data in H1 2024e. Given a challenging funding environment for Biotech companies, we judge that positive clinical results in 2023e-2024e will be critical to enable future capital raises.
LÄS MER
